CureVac Statistics

Total Valuation

CureVac has a market cap or net worth of GBP 536.90 million. The enterprise value is 194.23 million.

Market Cap	536.90M
Enterprise Value	194.23M

Important Dates

The next estimated earnings date is Friday, April 25, 2025.

Earnings Date	Apr 25, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+1.57%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	125.69M

Valuation Ratios

The trailing PE ratio is 4.00.

PE Ratio	4.00
Forward PE	n/a
PS Ratio	1.21
PB Ratio	0.93
P/TBV Ratio	0.97
P/FCF Ratio	7.42
P/OCF Ratio	6.37
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 1.10, with an EV/FCF ratio of 2.68.

EV / Earnings	1.45
EV / Sales	0.47
EV / EBITDA	1.10
EV / EBIT	1.20
EV / FCF	2.68

Financial Position

The company has a current ratio of 7.28, with a Debt / Equity ratio of 0.06.

Current Ratio	7.28
Quick Ratio	7.11
Debt / Equity	0.06
Debt / EBITDA	0.17
Debt / FCF	0.45
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is 26.73% and return on invested capital (ROIC) is 20.26%.

Return on Equity (ROE)	26.73%
Return on Assets (ROA)	16.48%
Return on Invested Capital (ROIC)	20.26%
Return on Capital Employed (ROCE)	28.72%
Revenue Per Employee	489,577
Profits Per Employee	148,366
Employee Count	983
Asset Turnover	0.67
Inventory Turnover	8.34

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +23.51% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+23.51%
50-Day Moving Average	3.10
200-Day Moving Average	3.20
Relative Strength Index (RSI)	58.50
Average Volume (20 Days)	9,326

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	7.63

Income Statement

In the last 12 months, CureVac had revenue of GBP 442.58 million and earned 134.12 million in profits. Earnings per share was 0.60.

Revenue	442.58M
Gross Profit	355.22M
Operating Income	173.48M
Pretax Income	157.85M
Net Income	134.12M
EBITDA	184.05M
EBIT	173.48M
Earnings Per Share (EPS)	0.60

Full Income Statement

Balance Sheet

The company has 398.39 million in cash and 32.22 million in debt, giving a net cash position of 366.17 million.

Cash & Cash Equivalents	398.39M
Total Debt	32.22M
Net Cash	366.17M
Net Cash Per Share	n/a
Equity (Book Value)	576.07M
Book Value Per Share	2.57
Working Capital	375.50M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 84.23 million and capital expenditures -11.84 million, giving a free cash flow of 72.39 million.

Operating Cash Flow	84.23M
Capital Expenditures	-11.84M
Free Cash Flow	72.39M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 80.26%, with operating and profit margins of 39.20% and 30.30%.

Gross Margin	80.26%
Operating Margin	39.20%
Pretax Margin	35.67%
Profit Margin	30.30%
EBITDA Margin	41.59%
EBIT Margin	39.20%
FCF Margin	16.36%

Dividends & Yields

CureVac does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1.57%
Shareholder Yield	-1.57%
Earnings Yield	24.98%
FCF Yield	13.48%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

CureVac has an Altman Z-Score of 3.55.

Altman Z-Score	3.55
Piotroski F-Score	n/a